Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess...
Aeterna Zentaris (AEZS) lands IND FDA approval for the initiation of a Phase 2A trial to assess the firm's treatment for cancer cachexia. The firm says if its AEZS-130 drug is effective, subjects could receive more effective doses of chemotherapy and have a better functional status.
From other sites
at Zacks.com (Mar 23, 2015)
at CNBC.com (Nov 6, 2014)
at CNBC.com (Jan 9, 2013)
at CNBC.com (Mar 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs